KIT and hematologic disorder: CD117 antibody-mediated immunological conditioning has the advantage of avoiding the toxicity of cytotoxic regimens applied in alloHSCT, is currently being clinically evaluated in benign hematologic diseases, and has shown encouraging preliminary data in terms of safety and activity.55